Compare Avient Corporation (AVNT) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Hims and Hers Health Inc — how do they compare? Avient Corporation trades at $35.96 (market cap $3.28B), while Hims and Hers Health Inc trades at $36.58 (market cap $8.14B). The key difference: Hims and Hers Health Inc is far larger — about 2.5× Avient Corporation's market cap, and Avient Corporation pays a 3.07% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| AVNT | HIMS | |
|---|---|---|
Market Cap | $3.28B | $8.14B |
Sector | Technology | Health |
52-Week High | $43.28 | $66.18 |
52-Week Low | $27.48 | $14.52 |
Enterprise Value | $4.78B | $8.52B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient Corporation (AVNT) trades at $35.57, down 1.28% with a bearish technical signal. The company shows consistent earnings beats with Q1 2026 EPS of $0.83 exceeding expectations. Fundamentals reveal a P/E of 20.79 and net income margin of 4.81%, while cash flow trends improved from -$34M in 2025 to -$28M projected for 2026. Recent developments include new product launches and ClassNK approval for Dyneema DM20 fiber, supporting growth in renewable energy markets.
AVNT presents a mixed outlook with strong analyst support (60% buy ratings) offset by near-term technical weakness. The company's innovation pipeline and cost control measures provide upside potential, though macroeconomic headwinds and competitive pressures remain key risks. Earnings growth and successful market expansion of new technologies are critical catalysts for stock performance.
Hims & Hers Health trades at $34.38, showing no change in the last session. The stock exhibits a bullish technical setup with moving averages supporting upward momentum, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing expectations, but revenue growth remains positive. Analyst sentiment is divided with a 35% buy rating, and the consensus price target is $33.57. News highlights include expansion in weight-loss treatments and a new JPMorgan receivables facility.
The outlook for HIMS is cautiously optimistic, driven by growth in telehealth and weight-loss segments, but high valuation multiples and recent net income declines pose risks. Investment opportunity lies in market expansion and subscriber growth, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
